EP0429039B1 — Use of an opiate antagonist for the preparation of a pharmaceutical composition to be transdermally administered, and device for transdermal delivery
Assigned to Alko Oy AB · Expires 1995-03-08 · 31y expired
What this patent protects
The use of an opiate antagonist for the preparation of a pharmaceutical composition to be transdermally administered simultaneously or separately sequentially with alcohol and a device for transdermally administering the antagonist. The device is a package containing a fixed dose…
USPTO Abstract
The use of an opiate antagonist for the preparation of a pharmaceutical composition to be transdermally administered simultaneously or separately sequentially with alcohol and a device for transdermally administering the antagonist. The device is a package containing a fixed dose of opiate antagonist, a vehicle and a permeation enhancer.
Drugs covered by this patent
- naloxone-hydrochloride (Naloxone Hydrochloride) · Pfizer Inc.
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.